BioMérieux Patents – Key Insights and Stats

BioMérieux has a total of 6078 patents globally, out of which 1061 have been granted. Of these 1839 patents, more than 44% patents are active. The United States of America is where BioMérieux has filed the maximum number of patents, followed by Europe and Japan. Parallelly, The United States of America seems to be the main focused R&D center and also France is the origin country of BioMérieux.

BioMérieux was founded in the year 1963. The Company provides diagnostic solutions and also offers vaccines and biological products for diagnosis of infectious diseases such as hepatitis, tuberculosis, respiratory infections, and cancer. BioMérieux serves patients worldwide.

Do read about some of the most popular patents of BioMérieux which have been covered by us in this article and also you can find BioMérieux patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over BioMérieux patent portfolio.

How many patents does the Founder and CEO of BioMérieux have?

The Founder Alain Mérieux has 0 patents and the CEO Alexandre Merieux have 0 patents.

How many patents does BioMérieux have?

BioMérieux has a total of 6078 patents globally. These patents belong to 1406 unique patent families. Out of 6078 patents, 2696 patents are active.

How Many Patents did BioMérieux File Every Year?

BioMérieux Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantbioMérieux Applications FiledbioMérieux Patents Granted
202336
202221166
202183187
2020131201
2019110224
2018192283
2017202236
2016279262
2015305239
2014365227
2013404169
2012407125
2011337117

How many BioMérieux patents are Alive/Dead?

Worldwide Patents

BioMérieux Patents Portfolio

How Many Patents did BioMérieux File in Different Countries?

BioMérieux Worldwide Patents

Countries in which BioMérieux Filed Patents

CountryPatents
United States Of America958
Europe891
Japan512
Germany494
France437
China436
Australia319
Spain297
Austria162
Canada162
India139
Brazil95
Hong Kong (S.A.R.)88
Korea (South)65
New Zealand64
Mexico49
Italy28
Denmark27
Portugal25
Poland22
Israel22
Singapore20
Russia19
Eurasia16
United Kingdom15
South Africa9
Slovenia8
Hungary4
Taiwan3
Cyprus3
Croatia3
Norway3
Africa3
Malta2
Belgium2
Turkey2
Albania2
Indonesia2
Ireland2
Chile2
San Marino2
Colombia1
Switzerland1
Serbia1
Sweden1

Where are Research Centers of BioMérieux Patents Located?

Research Centers of BioMérieux Patents

10 Best BioMérieux Patents

US7387887B2 is the most popular patent in the BioMérieux portfolio. It has received 205 citations so far from companies like Life Technologies Corporation, BD and Helix, Inc.

Below is the list of 10 most cited patents of BioMérieux:

Publication NumberCitation Count
US7387887B2205
US20060046246A1153
US6489114B2138
US6635427B2137
US6686195B1135
US6340571B1133
US8394608B2130
US6342396B1111
US20070240986A1111
US20100129857A197

How many inventions of other companies were rejected due to BioMérieux patents?

The statistics below share strategic R&D insights. It tells the companies that were trying to protect inventions similar to BioMérieux invention. They couldn’t because BioMérieux had protected those before them.

Examiners at the USPTO referred 813 BioMérieux patents in 205 rejections (35 USC § 102 or 35 USC § 103 types).

The top citing companies in the BioMérieux patent portfolio are Biofire Diagnostics, Capital Royalty Partners and Canon.

List of the Companies whose Patents were rejected citing BioMérieux –

CompanyNumber of Patent Applications that faced Rejection Citing bioMérieux PatentsNumber of Rejections (102 & 103)
Biofire Diagnostics1424
Capital Royalty Partners Ii Lp1220
Canon1122
Becton Dickinson613
Arkray610
Parallel Investment Opportunities Partners Ii Lp610
Roche Molecular Systems Inc510
Siemens Healthcare Diagnostics Ltd511
IBM57
Philips46

Count of 102 and 103 Type Rejections based on BioMérieux Patents

Top BioMérieux Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US8394608B212
US20060046246A110
US8841118B29
US8895295B29
US7387887B29
US6635427B28
US20090178935A17
US7630837B26
US20040197833A16
US20020052419A15
US11150250B25
US9029093B25
US9733261B24
US7456281B24
US7159618B24

What Percentage of BioMérieux US Patent Applications were Granted?

BioMérieux (Excluding its subsidiaries) has filed 659 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 495 have been granted leading to a grant rate of 79.97%.

Below are the key stats of BioMérieux patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for BioMérieux?

Law FirmTotal ApplicationsSuccess Rate
Oliff Plc19871.35%
Biomerieux Inc12888.43%
Myers Bigel4485.00%
Mcdonnell Boehnen Hulbert & Berghoff3484.38%
Alston & Bird29100.00%
James C Lydon1656.25%
Nicolas E Seckel1475.00%
Oblon Mcclelland Maier & Neustadt1392.31%
Parker Highlander Pllc1369.23%
Arlington Ladas & Parry1283.33%

What are BioMérieux‘s key innovation segments?

What Technologies are Covered by BioMérieux?

The chart below distributes patents filed by BioMérieux in different countries on the basis of the technology protected in patents. It also represents the markets where BioMérieux thinks it’s important to protect particular technology inventions.

R&D Focus: How has BioMérieux search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by BioMérieux?

Table of Content

Insights you may find interesting

Related Articles

Was this article helpful?

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.